Detecting Antidepressant Efficacy

Detecting Antidepressant Efficacy Supplementary Data Page 1

SUPPLEMENTARY DATA

Supplemental Table S1. Characteristics of Individual Studies Included in Meta-Analysis

V014* 1996 6 Placebo 102 101 23.6 (21.0) 76.5 24 38.6 Nemeroff & Venlafaxine IR 75 to 225 mg/d 100 96 24 56.3 Thase, 2007

V203 1987 6 Placebo 92 92 25.5 (22) 56.7 38 30.4 Rudolph et al, Venlafaxine IR 75, 225, or 375 mg/d 266 231 126 50.2 1998b

V208 1994 12 Placebo 100 99 24.49 (22) 65 41 32.3 Cunningham, Venlafaxine ER/IR 75 to 150 mg/d 193 179 66 61.5 1997

V209 1995 8 Placebo 102 100 24.5 (21) 66 41 29 Thase, 1997 Venlafaxine ER 75, 150, or 225 mg/d 95 91 26 58.2

V211* 1995 8 Placebo 98 97 25.4 (22.5) 79.8 21 42.3 Rudolph & Venlafaxine ER 75 to 225 mg/d 100 95 19 56.8 Feiger, 1999

V301* 1988 6 Placebo 78 78 24.96 (22) 68.9 21 39.7 Schweizer Venlafaxine IR 75 to 225 mg/d 73 64 26 65.6 et al, 1994

V302* 1988 6 Placebo 76 75 24.68 (22) 67.6 27 40 Cunningham Venlafaxine IR 75 to 200 mg/d 72 65 21 47.7 et al, 1994

V303* 1988 6 Placebo 80 79 24.13 (22) 65.4 24 40.5 Unpublished Venlafaxine IR 75 to 225 mg/d 79 70 31 52.9

V313† 1989 6 Placebo 78 75 25.5 (23) 73.9 24 34.7 Mendels et al, Venlafaxine IR 150 to 200 mg/d 79 77 17 47.3 1993 Detecting Antidepressant Efficacy Supplementary Data Page 2

Number Baseline Number Mean (Median) Completion Drop- Response Year Duration, (Safety), (ITT), HAM-D, rate, %, outs, N, rate, %, Study Initiated weeks Drug and Dose Arms per arm per arm total group total group per arm per arm Reference V342 1992 12 Placebo 98 93 24.7 (22) 52.1 44 28 Khan et al, Venlafaxine IR 75, 150 or 200 mg/d 286 253 140 43.9 1998 V360* 1995 12 Placebo 119 118 27.4 (25) 65.6 48 42.4 Silverstone & Venlafaxine ER 75 to 225 mg/d 128 122 37 66.4 Ravindran, 1999

V367* 1994 8 Placebo 83 79 26.7 (25) 98.4 24 56.8 Salinas, 1997 Venlafaxine ER 75 or 150 mg/d 165 157 46 63.7

V372* 1995 6 Placebo 152 139 24.3 (22) 71.8 44 37.4 Rudolph et al, Venlafaxine IR 200 to 375 mg/d 156 133 43 64.7 1998a

V384* 1997 6 Placebo 66 61 26.4 (25) 66.9 25 27.9 Unpublished Venlafaxine ER 225 to 375 mg/d 176 160 55 46.9

V402* 2000 10 Placebo 100 98 23 (23) 68.6 32 49 Unpublished Venlafaxine ER 75 to 300 mg/d 295 287 92 60.6

V414* 2000 10 Placebo 99 97 22.6 (22) 67.8 5 24.2 Unpublished Venlafaxine ER 75 to 300 mg/d 292 288 32 39.6

D309* 2004 8 Placebo 120 120 25.95 (25) 84 13 50 Lieberman Desvenlafaxine 200 or 400 mg/d 117 116 25 59.5 et al, 2008

D317* 2004 8 Placebo 125 125 25 (25) 78.2 17 44 Lieberman Desvenlafaxine 200 or 400 mg/d 114 110 35 50 et al, 2008

D223 2002 8 Placebo 78 78 22.20 (22) 73.4 20 42.3 Unpublished Desvenlafaxine 200 or 400 mg/d 144 135 39 47.4

D304 2003 8 Placebo 117 114 23.7 (23) 76.9 24 34.2 Liebowitz Desvenlafaxine 100 or 200 mg/d 121 120 31 43.3 et al, 2007 Detecting Antidepressant Efficacy Supplementary Data Page 3

Number Baseline Number Mean (Median) Completion Drop- Response Year Duration, (Safety), (ITT), HAM-D, rate, %, outs, N, rate, %, Study Initiated weeks Drug and Dose Arms per arm per arm total group total group per arm per arm Reference D306 2003 8 Placebo 120 118 23 (23) 76.6 22 34.7 DeMartinis Desvenlafaxine 100, 200, or 400 mg/d 350 343 88 47.8 et al, 2007

D308 2003 8 Placebo 125 124 25.1 (25) 75.1 27 37.9 Septien-Velez Desvenlafaxine 200 or 400 mg/d 248 245 66 58.4 et al, 2007

D320 2004 8 Placebo 118 118 23.2 (23) 81.3 15 30.5 Feiger et al, Desvenlafaxine 200 or 400 mg/d 117 117 29 39.3 2009

D332 2006 8 Placebo 152 150 23.25 (23) 80 25 44 Liebowitz Desvenlafaxine 50 or 100 mg/d 299 297 65 52.2 et al, 2008

D333 2006 8 Placebo 161 161 24.33 (24) 89.7 13 49.7 Boyer et al, Desvenlafaxine 50 or 100 mg/d 325 322 37 64.3 2008

D335* 2008 8 Placebo 161 160 23.62 (23.5) 77.5 38 38.1 Tourian et al, Desvenlafaxine 50 or 100 mg/d 298 298 61 43.6 2009

D403 2006 8 Placebo 125 125 20.72 (21) 84 16 32.8 Kornstein et al, Desvenlafaxine 100 or 200 mg/d 256 247 45 55.5 2010

D3359† 2008 8 Placebo 231 231 22.93 (22) 90.8 22 34.6 Iwata et al, n.d. Desvenlafaxine 50 mg/d 236 236 21 46.2

D3362† 2009 8 Placebo 223 223 23.16 (23) 88.8 28 38.1 Liebowitz Desvenlafaxine 50 mg/d 224 224 22 40.6 et al, n.d.

D4415 2010 12 Placebo 142 142 21.95 (22) 79.2 35 46.5 Dunlop et al, Desvenlafaxine 50 mg/d 285 285 54 60.7 2011

HAM-D, Hamilton Rating Scale for Depression; ITT, intent to treat; n.d., no date.

*Study included an active control arm, not included in analyses. †Study included ≥1 lower dose arms, not included in the analyses. Detecting Antidepressant Efficacy Supplementary Data Page 4 Detecting Antidepressant Efficacy Supplementary Data Page 5

References for Supplemental Table

Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R, et al (2008). Efficacy,

safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder

in a placebo-controlled trial. Int Clin Psychopharmacol 23: 243-253.

Cunningham LA; Venlafaxine XR 208 Study Group. Once-daily venlafaxine extended release (XR)

and venlafaxine immediate release (IR) in outpatients with major depression (1997). Ann Clin

Psychiatry 9: 157-164.

Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, et al (1994). A

comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 14:

99-106.

DeMartinis NA, Yeung PP, Entsuah R, Manley AL (2007). A double-blind, placebo-controlled study

of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J

Clin Psychiatry 68: 677-688.

Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ (2011). Symptomatic and

functional improvement in employed depressed patients: a double-blind clinical trial of

desvenlafaxine versus placebo. J Clin Psychopharmacol 31: 569-576.

Feiger AD, Tourian KA, Rosas GR, Padmanabhan SK (2009). A placebo-controlled study evaluating

the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive

disorder. CNS Spectr 14:41-50.

Iwata N, TourianKA , Hwang E, Mele L, Vialet C, for the Study 3359 Investigators. Efficacy and

safety of desvenlafaxine 25 and 50 mg/d in a randomized, placebo-controlled study of depressed

outpatients. Manuscript submitted for publication. Detecting Antidepressant Efficacy Supplementary Data Page 6

Khan A, Upton GV, Rudolph RL, Entsuah R, Leventer SM (1998). The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study.

Venlafaxine Investigator Study Group. J Clin Psychopharmacol 18: 19-25.

Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ (2010). Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry 71: 1088-1096.

Lieberman DZ, Montgomery SA, Tourian KA, Brisard C, Rosas G, Padmanabhan K, et al (2008). A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int

Clin Psychopharmacol 23: 188-197.

Liebowitz MR, Yeung PP, Entsuah R (2007). A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 68:

1663-1672.

Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder (2008). Curr Med Res Opin 24: 1877-1890.

Liebowitz MR, Tourian KA, Hwang E, Mele L, for the Study 3362 Investigators. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and

50 mg/d in adult outpatients with major depressive disorder. Manuscript submitted for publication.

Mendels J, Johnston R, Mattes J, Riesenberg R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study (1993). Psychopharmacol Bull 29: 169-174.

Nemeroff CB, Thase ME; EPIC 014 Study Group. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients (2007). J Psychiatr Res 41: 351-359. Detecting Antidepressant Efficacy Supplementary Data Page 7

Rudolph R, Aguiar L, Entsuah R, Derivan A (1998a). Early onset of antidepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study. Eur

Neuropsychopharmacol 8 (suppl 3). Abstract P.1.027.

Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT (1998b). A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 59: 116-122.

Rudolph R, Feiger A (1999). A double-blind, randomised, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 56:

171-181.

Salinas E, for the Venlafaxine XR 367 Study Group (1997). Once daily extended release (XR) venlafaxine versus paroxetine in outpatients with major depression. Biol Psychiatry 42 (suppl 1):

244s. Abstract 90-49.

Schweizer E, Feighner J, Mandos LA, Rickels K (1994). Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 55: 104-108.

Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA (2007). randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 22: 338-347.

Silverstone PH, Ravindran A; Venlafaxine XR 360 Study Group (1999). Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin

Psychiatry 60: 22-28. Detecting Antidepressant Efficacy Supplementary Data Page 8

Thase ME, The Venlafaxine XR 209 Study Group (1997). Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry 58: 393-

398.

Tourian K, Padmanabhan S, Groark J, Brisard C, Farrington D (2009). Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8 week, phase III, multicenter, randomized, double blind, placebo controlled parallel group trial and a post hoc analysis of 3 studies. ClinTher 31:

1405-1423.